Name change for Epistem as it raises £6.5m
MANCHESTER biotech company Epistem Holdings has raised £6.5m through a share placing, to broaden the portfolio of its Genedrive tests, developed to fight infectious diseases such as TB across the globe.
The new ordinary shares will represent 43.5% of the company's enlarged share capital.
Cornerstone investor Calculus Capital subscribed for 3,125,000 placing shares, investing £2.5m of the total £6.5m raised and will hold 16.7% of the enlarged share capital.
The listed company has also announced ... For the full story register now for free or login below...